**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Mario Nuvolone
Department of Molecular Medicine, University of Pavia, Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

**Main Body of the Abstract**
Current staging and response criteria in AL amyloidosis stemmed from retrospective studies limited by sample size, patient selection, and lack of molecular data. Moreover, validated hematologic progression criteria are still lacking.
In the frame of the EUREKA Consortium (NCT06205953), funded by the European Joint Program for Rare Diseases, we have started to create a large prospective registry collecting all new, consecutive cases of AL amyloidosis evaluated at 4 referral Centers across Europe (Pavia-Italy; Heidelberg-Germany; Utrecht-The Netherlands; Pamplona-Spain) or at their satellite sites. The prospective, REDCap-based registry is linked to a cross-border biorepository and sample sharing network for molecular/phenotypic profiling of clonal plasma cells (RNA sequencing, low-pass WGS, circulating tumor cell analysis) and light chains (sequencing, N-glycosylation analysis and phenotypic assessment in a 3D heart-on-a-chip model). A fifth site (Muttenz-Switzerland) endows big data analysis and artificial intelligence applied to health.
We aim at:
-defining the impact of molecular profiling on disease phenotype to promote early diagnosis and patients’ stratification and to guide therapeutic choices;
-describing real-world presentation (including subjects who are usually excluded from clinical trials), access to treatments, and outcome (including quality of life);
-defining the role of standard and new tools for assessing minimal residual disease after treatment.
Besides deepening our current understanding of the biology of AL amyloidosis, the data produced within this study will be instrumental in promoting early diagnosis, personalizing individual patient management and in the design of future clinical trials. The Consortium is open to other centers worldwide wishing to contribute to this study.



A EUropean REgistry and sample sharing networK to promote the diagnosis and management of light chain Amyloidosis: The EUREKA study PA132 (#490)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.